Tergaze Inj. is a recombinant human hyaluronidase formulation developed based on Alteogen's proprietary recombinant technology, HYBROZYME™ Technology.
|
Active Ingredient |
Recombinant human hyaluronidase 1500 IU/mL (In accordance with Ph. Eur. hyaluronidase assay) |
|
Mechanism of Action and Effects |
• Facilitates the absorption and dispersion of drugs and local anesthetics during subcutaneous injection, intramuscular injection, and subcutaneous infusion. • Promotes the resorption of excess fluids and blood accumulated in tissues. |
|
Product Features |
• High-Purity Human-Derived Hyaluronidase: Enhanced safety is expected due to the reduction of impurities and foreign proteins. • Superior Safety: Avoids the risks of viral infection and genotoxicity commonly associated with animal-derived formulations. • Recombinant DNA Technology: Manufacturing based on recombinant technology ensures uncompromised product consistency and quality stability. • Safety Evaluation: Efficacy and safety evaluations have been successfully completed in large-scale global clinical trials, including in South Korea. |
|
Clinical Applications |
• Plastic Surgery: Breakdown of hyaluronic acid preparations (e.g., fillers) and management of associated side effects. When co-administered during injection therapies aimed at double chin improvement, this formulation promotes the diffusion of the drug within the tissues, contributing to a more uniform local drug distribution. It is also expected to alleviate swelling and pain associated with lifting procedures. • Internal Medicine / Oncology: Enhancement of drug delivery efficiency and tissue diffusion. • Emergency Medicine / Ophthalmology: Emergency management of conditions such as edema and hematomas. |
|
HYBROZYMETM Technology
|
A proprietary subcutaneous (SC) formulation platform technology developed by the South Korean biotech company Alteogen. It plays a pivotal role in converting oncology and protein drugs—previously limited to intravenous (IV) administration—into SC formulations that enable convenient self-administration at home. This innovative technology has been successfully out-licensed to multiple leading global pharmaceutical companies.
• MSD: Signed an exclusive agreement for the subcutaneous formulation of Keytruda, the world's top-selling immunotherapy. • Daiichi Sankyo: Entered into a technology partnership agreement to develop a subcutaneous formulation of Enhertu, a next-generation oncology drug. • Global Collaborations: Collaborating with more than six global pharmaceutical companies, including Sandoz and AstraZeneca. |
